Michael Lyman is the Head of Discovery Research at IconOVir Bio. Prior to joining IconOVir, Michael was the Director of Translational Research at the Salk Institute of Biological Studies where he led a translational research team working with Clodagh O’Shea to develop a pipeline of novel virus-based therapies including oncolytic viruses. Before going to the Salk, he was the Associate Director of Immunology at Tanabe Research Laboratories (a San Diego based subsidiary of the Mitsubishi Tanabe Pharma Corporation) where he and his research team were responsible for the discovery and non-clinical research efforts for multiple biologics programs in the therapeutic areas of inflammatory disease and autoimmunity. He also played a key role in out-licensing activities for Tanabe’s lead pre-clinical stage program, a novel bi-specific targeting IL-6R and IL-17A. Prior to that, he was a scientist at Kyowa Hakko Kirin California (formerly Kirin Pharmaceuticals), where he was a project leader and major contributor to two separate therapeutic antibody programs that reached the clinic.
Before joining the pharmaceutical industry, Michael received his Ph.D. in Immunology and Microbial Pathogenesis from Northwestern University and did his postdoctoral work at the Scripps Research Institute.